Enclomiphene
As of the edition of 20 October 2026, Enclomiphene is a small molecule: went quiet in 2017; acts on ESR1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Went quiet, 2017
- Kind
- Small molecule
- Registered trials
- 25, 1 stopped early
- Disease areas
- Hormones; Nutrition and metabolism; Urinary and reproductive
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| ESR1 | Estrogen receptor | P03372 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 9 | 9 | 0 | 0 |
| Phase 2 | 6 | 6 | 0 | 0 |
| Phase 3 | 10 | 9 | 0 | 1 |
| All trials | 25 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| AbbVie | Lead sponsor of trials | 2006 to now |